Saturday 17 October 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024. In the quarter to June 2026, revenue fell 98.4%, EPS grew 86.8% and free cash flow fell 5.22%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.58
0.04
−6.45%
Follow APRE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 19.45 | 19.32 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (1.88) | (2.97) | |
P/B ratio |
— | — | 0.45 | 0.86 | |
Price to Tangible BV |
— | — | 0.45 | 0.86 | |
EV/Sales |
— | — | (31.65) | (8.78) | |
EV/EBITDA |
— | — | 0.68 | 0.31 | |
EV/Operating CF |
— | — | 0.70 | 0.32 | |
EV/FCF |
— | — | 0.70 | 0.32 | |
Quick Ratio |
13.33 | 8.77 | 5.28 | 5.12 | |
Current Ratio |
13.55 | 8.92 | 5.63 | 5.20 | |
Net Debt/EBITDA |
10.24 | 13.57 | 5.53 | 4.41 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.02 | |
Operating CF/Net income |
0.91 | 0.84 | 1.21 | 1.07 | |
Capex/Depreciation |
(2.66) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 30,569.70% | 91,050.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 49,624.24% | 82,238.89% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 3,303.03% | 6,316.67% | |
Graham Net Nets |
— | — | 2.17 | 1.12 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (232.94%) | (145.27%) | |
Free Cash Flow Yield |
— | — | (232.27%) | (142.70%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.06) | (0.19) | (0.45) | (0.50) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.19) | (0.45) | (0.50) | |
Cash per Share |
0.77 | 3.16 | 2.23 | 2.15 | |
Shareholders Equity per Share |
0.72 | 2.83 | 1.90 | 1.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.72 | 2.83 | 1.90 | 1.71 | |
Free Cash Flow |
(3.29) | (2.76) | (2.96) | (3.17) | |
Working Capital |
38.82 | 41.95 | 12.80 | 11.26 | |
Capital Expenditures |
(0.02) | — | — | — | |
Net Current Asset Value |
38.09 | 41.22 | 12.07 | 10.54 | |
EV/EBIT |
— | — | 0.68 | 0.31 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.07 | 2.11 | 1.03 | 0.90 | |
Average Assets |
29.80 | 33.92 | 19.96 | 20.61 | |
Average Common Equity |
25.94 | 28.57 | 15.87 | 16.43 |
Columns are period end dates